Here at the European Association of Urology (EAU) congress in Paris, there are some interesting debates amongst delegates attending the meeting regarding new therapies either recently – or about to be approved – for castrate-resistant prostate cancer (CRPC).
- How should abiraterone and MDV3100 be sequenced pre or post chemotherapy?
- Would combining the two drugs post chemo be a better strategy that leads to superior outcomes?
- Where does chemotherapy fit into this emerging paradigm? Do we need chemotherapy in an new era of oral therapies? If yes, which patients should be considered eligible?